MorphoSys (ETR:MOR) has been assigned a €130.00 ($151.16) target price by equities researchers at JPMorgan Chase & Co. in a research note issued on Monday, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 27.20% from the stock’s previous close.
A number of other research analysts also recently weighed in on the stock. Independent Research set a €110.00 ($127.91) target price on shares of MorphoSys and gave the company a “neutral” rating in a research report on Friday, November 1st. Royal Bank of Canada set a €130.00 ($151.16) price objective on shares of MorphoSys and gave the stock a “buy” rating in a report on Thursday, November 7th. Berenberg Bank set a €145.00 ($168.60) price objective on shares of MorphoSys and gave the stock a “buy” rating in a report on Monday, November 11th. Deutsche Bank set a €129.00 ($150.00) price objective on shares of MorphoSys and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, Goldman Sachs Group set a €114.00 ($132.56) price objective on shares of MorphoSys and gave the stock a “neutral” rating in a report on Tuesday, October 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. MorphoSys has an average rating of “Buy” and an average price target of €119.38 ($138.81).
Shares of MorphoSys stock traded up €7.10 ($8.26) on Monday, reaching €102.20 ($118.84). 420,385 shares of the company traded hands, compared to its average volume of 153,687. MorphoSys has a 52 week low of €79.70 ($92.67) and a 52 week high of €114.70 ($133.37). The company has a 50 day moving average of €99.02 and a 200 day moving average of €97.24. The firm has a market capitalization of $3.24 billion and a PE ratio of -33.60. The company has a debt-to-equity ratio of 9.78, a current ratio of 7.80 and a quick ratio of 7.63.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Featured Story: Dividend Aristocrat Index
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.